You are here: Industry Insights > Mithra

News List

Mayne Pharma and Mithra Announce TGA Approval of NEXTSTELLIS® Oral Contraceptive prnasia
November 30, 2021
Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce the Therapeutic Goods Administration (TGA) has approved the novel combined oral contraceptive...
ExeVir, Mithra CDMO Enter Manufacturing Collaboration contractpharma
July 21, 2021
Manufacturing of ExeVir's candidate product for Covid-19 Treatments will take place at Mithra CDMO's new injectable facility.
Mithra Completes Recruitment of Covid-19 Phase II Study firstwordpharma
June 18, 2021
Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has completed recruitment of the Coronesta Phase II, aiming to assess the protective role of Estetrol in Covid-19 infection.
Deals this week: Mithra, Hainan Haiyao, TherapeuticsMD pharmaceufical-technology
September 30, 2017
Belgium-based pharmaceutical company Mithra has signed a licensing agreement with Brazilian biopharmaceutical company Libbs to commercialise its Estelle oral contraceptive (COC) product in Brazil.
Mithra and Libbs partner to commercialise Estelle oral contraceptive in Brazil pharmaceufical-technology
September 27, 2017
Mithra's Estelle is a new oral contraceptive product candidate that comprises 15mg of Estetrol (E4), its unique native estrogen and 3mg of Drospirenone (DRSP).
USPTO issues Notice of Allowance for Mithra’s application for Estetrol patent pharmaceutical-technology
January 20, 2017
The US Patent and Trademark Office (USPTO) has issued patent allowance for Belgium-based Mithra Pharmaceuticals’ Estetrol (E4) for use as an emergency contraceptive.